<div>
  <ul>
    <li>
      <p>
        Chinese medical researchers from Xijing Hospital of the Air Force Medical University have announced the successful transplanting of a genetically modified pig kidney into a brain-dead person. This follows the previous success of pig liver transplantation in March.
      </p>
    </li>
    <li>
      <p>
        The surgical team, led by Dr. Qin Weijun, transplanted the gene-edited pig kidney into the patient's right iliac fossa. The operation lasted over six hours and resulted in the immediate production of urine from the transplanted kidney, indicating it was functioning properly without signs of hyperacute rejection. The researchers believe the studies could potentially lead to providing alternative solutions for patients with end-stage renal disease. It's also seen as an effective method to address organ shortages, credited to advancements in gene editing technology and immunology. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


Human Gene Editing

PROMINENT_CATEGORY

<div>
 <p>Chinese medical researchers from Xijing Hospital of the Air Force Medical University have successfully transplanted a genetically modified pig kidney into a brain-dead person. This accomplishment follows a successful pig liver transplantation earlier in the year. </p>
 <p>Dr. Qin Weijun led the surgical team performing the kidney transplant, which was placed in the patient's right iliac fossa. The operation took over six hours and resulted in the immediate function of the kidney, as demonstrated by the production of urine. There was no evidence of hyperacute rejection. Research suggests that this technique could provide new solutions for end-stage renal disease and help to address organ shortages. This success largely owes to advancements in gene editing technology and immunology.</p>
 
</div>

Chinese researchers successfully transplant genetically modified pig kidney to human body

<div>
 <p>SOHM, a biopharmaceutical company, has developed a partnership with Coastar Therapeutics to refine genome editing technology. This partnership will utilize SOHM's ABBIE (A Binding Based Integrase Enzyme) genome-editing tool in conjunction with Coastar's red blood cell membrane-derived carriers.</p>
 <p>The objective of their collaboration is to augment the effectiveness of genome editing through improved delivery of therapeutic cargo. Their aim is to achieve greater precision by targeting specific cells, and to establish a flexible, scalable platform for efficient genome editing applicable to various cell types and tissues.</p>
 <p>SOHM's work is focused on researching and developing gene editing technologies for their utilization in therapeutic applications, concentrating on precision medicine. Its product portfolio has been expanded to include gene-editing technologies such as ABBIE, a gene-editing platform procured in September 2023, thus strengthening its proficiency in the biotech sector.</p>
</div>

SOHM, Inc. partners with Coastar Therapeutics to advance genome-editing technologies

<div>
 <p>Sangamo Therapeutics, a gene editing company from California, has inked a securities purchase and sale deal with institutional investors. Under the agreement, approximately 24.7 million shares of common stock and pre-funded warrants to acquire around 3.8 million shares of common stock will be purchased and sold. This deal also includes warrants to purchase up to 28.5 million shares of common stock.</p>
 <p>Each common stock and its corresponding warrant are priced at USD 0.84. Each pre-funded warrant plus an accompanying warrant carry a price of USD 0.83. These warrants can be exercised six months after issue and are valid for five and a half years, with an exercise price of USD 1.00 per share. The close of the offering is anticipated on March 26, 2024.</p>
 <p>The funds raised from this offering will be used for various purposes. Primarily, they will be employed to develop a genomic medicines pipeline focused on neurology, promote the AAV capsid delivery technology, and cover other general corporate needs.</p>
 
</div>

Sangamo Therapeutics announces USD 24 million in registered direct offering to develop neurology pipeline

<div>
 <p>Profluent, an AI-based protein engineering company, has raised an additional USD 35 million in its latest venture funding round. This round was led by Spark Capital and saw participation from existing investors Insight Partners, Air Street Capital, and several angel investors. This additional funding followed the company's seed round in August 2022, which raised USD 9 million, bringing the total funds raised to USD 44 million.</p>
 <p>These funds are set to propel the company into its next growth phase. This includes enhancing its unique proprietary LLMs and datasets, broadening wet lab capabilities, and improving the efficiency of CRISPR gene-editing systems.</p>
 <p>Founded recently in 2022, Profluent uses GenAI models to understand the genetic code's language. This know-how aids in designing and validating new and functional proteins to make advancements in biomedicine. Their key aim lies in designing unique, functional proteins that can address limitations in the existing industry.</p>
</div>

Profluent raises USD 35 million in venture funding to accelerate company’s growth

<div>
 <p>Intellia Therapeutics, a gene-editing biotech company based in Massachusetts, has begun the Phase III MAGNITUDE trial for its CRISPR-based therapy, NTLA-2001. The therapy is intended for the treatment of transthyretin (ATTR) amyloidosis, a fatal and progressive heart condition.</p>
 <p>The goal of the therapy is to provide a successful single-dose treatment for patients with ATTR amyloidosis alongside cardiomyopathy. It is believed to be the first therapy that uses CRISPR to edit genes systematically within the human body.</p>
</div>

Intellia Therapeutics initiates Phase III trial for CRISPR-based heart disease treatment

<div>
 <p>EmendoBio, a CRISPR gene-editing company from the US, and Anocca AB, a Swedish firm specializing in cell development, have entered into a non-exclusive licensing agreement. The agreement will allow use of EmendoBio's OMNI-A4 nuclease in efforts to speed up the development of therapies for solid cancer. The specifics and financial details of the agreement are yet to be disclosed.</p>
 <p>This partnership entails the integration of the OMNI-A4 nuclease from EmendoBio into Anocca's manufacturing procedures, with the objective to improve the quality of cell therapy products and increase the production of TCR T products. This collaboration is set to facilitate Anocca's aim to fast-track the initiation of its first clinical program. This program is aimed at targeting the KRAS driver mutation in hard-to-treat solid cancers.</p>
</div>

EmendoBio and Anocca enter non-exclusive licensing agreement to accelerate TCR T-cell therapy for solid cancers

<div>
 <p>Arbor Biotechnologies, a Massachusetts-based AI-powered gene editing company, and Allogene Therapeutics, a California-based cell therapy company, have signed a non-exclusive, global licensing agreement to develop gene-editing treatments for autoimmune diseases. The agreement will see the integration of Arbor's CRISPR gene-editing technology into Allogene's AlloCAR T platform.</p>
 <p>This cooperation aims to create a widely applicable Chimeric Antigen Receptor T-cell (CAR T) treatment for autoimmune disease. Allogene's AlloCAR T product for autoimmune conditions is projected to commence Phase I clinical trials in early 2025.</p>
 
</div>

Arbor Biotechnologies and Allogene Therapeutics announce global gene-editing licensing agreement to treat CAR T autoimmune disease

ANALYST_QUICK_TAKE

<div>
 
 <p>iECURE, a gene-editing company based in Pennsylvania, has been granted Clinical Trial Authorisation (CTA) by the UK Medicines &amp; Healthcare products Regulatory Agency to proceed with the Phase I/II OTC-HOPE trial expansion for ECUR-506. This therapy is designed to treat Ornithine Transcarbamylase (OTC) deficiency, a metabolic disorder inherited that affects infants.</p>
 <p>ECUR-506 works by introducing a functional OTC gene into the patient's body using ARCUS nuclease. This process utilizes two vectors: one for gene editing and one for deploying the necessary gene. One of the key features of the therapy is its ability to treat OTC deficiency using varying doses. The therapy is administered intravenously via a single dose.</p>
 
</div> <p><b>Analyst QuickTake</b> :<br>
 ECUR-506 is a medical approach that aims to treat genetic disorders by directly modifying an individual’s DNA. In <a href="https:<br>
//www.businesswire.com/news/home/20210909005309/en/Precision-BioSciences-and-iECURE-Announce-License-and-Collaboration-Agreement-to-Develop-ARCUS-Based-Gene-Editing-Therapies"> September 2021 </a> , the company secured a license for ARCUS nuclease, a gene editing platform from Precision Medicine to develop this therapy. In <a href="https:<br>
//iecure.com/news/iecure-secures-clearance-from-australian-therapeutic-goods-administration-for-its-clinical-trial-approval-for-the-otc-hope-phase-1-2-study-of-ecur-506/"> December 2023 </a> , the therapy was approved by the Australian Therapeutic Goods Administration (TGA).&nbsp;</p>

iECURE receives MHRA approval to expand clinical study in UK

<div>
 <p>The gene-editing company based in Durham, Precision BioSciences, has valued its public offering and sale at USD 16 per share. This offering includes 2.5 million common shares along with warrants to purchase an extra 2.5 million shares. This is anticipated to bring about a gross profit of about USD 40 million.</p>
 <p>The available warrants can be enacted immediately at USD 20 per warrant and will be valid for five years post issuance.</p>
 <p>The underwriters have also been granted an option to acquire 375,000 shares over a span of 30 days. The offering is scheduled to conclude around March 5, 2024.</p>
 <p>The received funds will be used for ongoing and projected R&amp;D operations, support for working capital, and general corporate objectives.</p> 
</div>

Precision BioSciences to secure USD 40 million in underwritten public offering

<div>
 <p>Prime Medicine, a firm specializing in CRISPR gene-editing, has finalized its expanded public offering. They sold 22.5 million shares of common stock at USD 6.25 per share, including a complete execution of underwriters' additional option for 3.4 million shares. Additionally, pre-funded warrants totaling 3.2 million shares were provided to specified investors at USD 6.43 each.</p>
 <p>From this offering, Prime Medicine raised a total of USD 161 million. However, the purpose for which these funds will be used has not yet been revealed.&nbsp;</p>
 
</div>

All Updates